Publication & events

August 1, 2009 ARVO Summer Eye Research Conference
Taligen Co-Founder and CSO Dr. Michael Holers served today in Bethesda MD as an invited session chair at the ARVO Summer Eye Research Conference “Ophthalmic Drug Delivery Systems for the Treatment of Retinal Diseases: Basic Research to Clinical Application”. He also presented a talk “Retinal Degeneration in the Spectrum of Systemic Diseases – Rationale for Target Selection” describing the rationale for the use of complement alternative pathway inhibitors in the treatment of age-related macular degeneration (AMD).
June 29, 2009 “1st International Conference on Inflammation and Retinal Disease: Complement Biology and Pathology” in Crete, Greece
Taligen Co-Founder and CSO Dr. Michael Holers served today at the “1st International Conference on Inflammation and Retinal Disease: Complement Biology and Pathology” in Crete, Greece as a session chair and also presented an invited talk “Development and description of two potent targeted therapeutics that modulate the alternative pathway of complement by either inhibition of factor B or supplementation of factor H activity”.
May 19, 2009 The International Conference “Current Diagnosis and Therapy of Hemolytic Uremic Syndrome (HUS)” in Innsbruck, Austria
Taligen Co-Founder Dr. Woody Emlen presented an invited talk today on new developments at Taligen Therapeutics at the International Conference “Current Diagnosis and Therapy of Hemolytic Uremic Syndrome (HUS)” in Innsbruck, Austria. Taligen consultant Dr. Joshua Thurman presented data on the use of the mouse analogue of human TT30 in an in vitro model of endothelial injury during aHUS.
May 5, 2009 ARVO Mtg in Ft. Lauderdale, FL
Taligen collaborator Dr. Barb Rohrer, along with co-authors and Taligen collaborators Steve Tomlinson and Joshua Thurman, presented today at the 2009 ARVO Mtg in Ft. Lauderdale, FL a talk entitled “A Dual-Hit Hypothesis in Retinal Pigmented Epithelial Cell Dysfunction: Oxidative Stress Renders Cells Susceptible to Complement-Mediated Injury”. Data included the positive effects of the mouse analogue of human TT30 in protecting retinal cells in vitro from complement activation initiated by oxidative injury.
July 22, 2008 “The spectrum of complement alternative pathway-mediated diseases” M. Holers
September 10, 2007 Dr. Holers and Taligen Collaborators present at International Complement Workshop
Dr. Michael Holers, Taligen’s CSO and Dr. Steve Tomlinson, a Taligen collaborator presented a total of 5 abstracts at the International Complement Workshop held in Cardiff, Wales, September 2007.
August 13, 2007 Taligen: De-amplifying complement (BioCentury; Emerging Company Profile, p11)
April 26, 2007 Dr. Emlen of Taligen to speak at the SMi Conference
Dr. Emlen of Taligen to speak at the SMi Conference on Asthma & COPD in London on Use of Complement-based Therapeutics in Asthma.
February 21, 2007 Taligen selected to present at Venture Capital of the Rockies
Dr. Woodruff Emlen will present an overview of Taligen at the VCiR conference 2/21/07
February 6, 2007 Taligen to Present at Biopartnering North America Conference, Vancouver, BC
Taligen has been selected as one of the emerging companies for presentation at the annual Biopartnering North America Conference.
December 4, 2006 Dr. Emlen, CEO of Taligen, to speak at CBI’s Airway Inflammation Drug Development Summit Conference
Dr. Emlen’s presentation entitled “A Novel Complement Inhibitor in the Treatment of Asthma” will give an overview of Taligen’s lead technology, TA106, and its development as a novel therapeutic for asthma.
October 25, 2006 Taligen collaborator presents at Eye Workshop in Argentina
Dr. Barbel Rohrer, in collaboration with Taligen, will present a paper entitled “Blocking alternative complement activation in an animal model of AMD” at the (MORE DETAILS TO FOLLOW)
October 23, 2006 Taligen Scientists to speak at International Complement Workshop in Beijing, China
Taligen’s co-founder, Dr. Michael Holers and Taligen-collaborators Drs. Tomlinson, Gilkeson and Thurman will present papers at the International Complement Workshop.
August 29, 2006 Taligen’s TA106 Could Be Lucky Charm Vs. Asthma
May 25, 2006 Dr. Emlen to speak at C21 conference
Taligen will present an overview of the Company and its Technology at the annual C21 conference in Monterrey, California on May 25.